Drugmaker Alkermes beats Q2 revenue estimates, keeps FY ouitlook

Alkermes

29/07/2025 12:17

Overview

Alkermes Q2 2025 revenue of $390.7 mln beats analyst expectations

GAAP net income for Q2 2025 was $87.1 mln with diluted EPS of $0.52

Revenue growth driven by strong performance of proprietary products

Outlook

Alkermes reiterates 2025 financial expectations as per Feb. 12 press release

Result Drivers

PROPRIETARY PRODUCT SALES - Strong performance across Vivitrol, Aristada, and Lybalvi drove revenue growth

MEDICAID UTILIZATION - Gross-to-net favorability from Medicaid adjustments contributed to revenue increase

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$390.70 mln
$341.60 mln (15 Analysts)
Q2 EPS
$0.52
Q2 Net Income
$87.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Alkermes Plc is $42.00, about 37.7% above its July 28 closing price of $26.15

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nPnVHmS5a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)